Profese online 2021, 14(2):14-21 | DOI: 10.5507/pol.2021.016

PERTUSSIS - RE-EMERGIGNG DISEASE

Kateřina Fabiánová
Státní zdravotní ústav Praha, Centrum epidemiologie a mikrobiologie, Oddělení epidemiologie infekčních nemocí, Česká republika

Background: Vaccination against pertussis in the Czech Republic (CR) was started at the end of 1958. Vaccination was maintained at a very good level for a long time and only a few cases per year were reported. Nevertheless, in the CR, pertussis has been on the rise (re-emerging disease) since the 1990s, similarly to other countries.

Aim: To get acquainted with the current epidemiological situation and possible factors that affect it.

Methods: An overview summarizing published studies and articles on the issue.

Results: Pertussis is on the rise in countries where acellular vaccine is being vaccinated, but also where whole cell vaccine is used. A change in the age distribution of the disease is observed with a shift to the group of adolescents and adults. Pertussis is a major cause of morbidity and mortality in infant. Acellular vaccines are considered safe, but there is growing evidence that acellular vaccines are not able to adequately control pertussis.

Conclusions: Pertussis can be prevented by vaccination. Despite the high vaccination coverage, pertussis is considered a re-emerging disease. It is necessary to improve all parts of surveillance, including early and correct diagnosis. It is important to put in place measures to reduce the transmission of pertussis to infant. Due to the increase in pertussis in the CR, it is necessary to maintain the highest possible vaccination coverage, especially in the population at increased risk of the disease.

Keywords: Pertuse, Bordetella pertussis, očkování, celobuněčná a acelulární vakcína, polymorfismus

Received: November 2021; Revised: November 2021; Accepted: November 2021; Published: December 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fabiánová, K. (2021). PERTUSSIS - RE-EMERGIGNG DISEASE. Profese Online, 14(2), 14-21. doi: 10.5507/pol.2021.016
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. WHO. WHO SAGE pertussis working group. Background paper. Sage April 2014. [online]. [cit. 2015-01-10] Dostupný na www: http://www.who.int/immunization/sage/meetings/2014/april/1_Pertussis_background_FINAL4_web.pdf.
    2. Gzyl A, Augustynowicz E, Rabczenko D, Gniadek G, Slusarczyk J. Pertussis in Poland. Int J Epidemiol. 2004;33(2):358-65. Go to original source... Go to PubMed...
    3. Fabiánová K, Beneš Č, Kříž B. A steady rise in incidence of pertussis since nineties in the CzechRepublic. Epidemiol Mikrobiol Imunol; 2010; 59(1):25-33
    4. Da Silva FR, De Albuquerque Navarro BM, L.T. Pinto LA, De-Simone SG. An overview of pertussis reemergence and evidence of its resurgence in Brazil. Rev Patol Trop. 2014;43(2): 151-62. Go to original source...
    5. Fabiánová K, Šebestová H, Beneš Č, Zavadilová J, Křížová P, Kříž B. Pertussis trend in children under one year of age in the Czech Republic in 1997-2013. Epidemiol Mikrobiol Imunol. 2014;63(4):270-7.
    6. Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson RM. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol. 2005;43(6):2856-65. Go to original source... Go to PubMed...
    7. Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ, de Greeff SC, Diavatopoulos D, Teunis P, Nagelkerke N, Mertsola J. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis. 2009;15(8):1206-13. Go to original source... Go to PubMed...
    8. Mooi FR, van Loo IH, King AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg Infect Dis. 2001;7(3 Suppl):526-8. Go to original source... Go to PubMed...
    9. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun. 1998;66(2):670-5. Go to original source... Go to PubMed...
    10. Zavadilová J, Lžičařová D, Musílek M, Křížová P, Fabiánová K. Antigenní variabilita kmenů Bordetella pertussis izolovaných v letech 1967-2010 v České republice - možné vysvětlení vzestupu onemocnění pertusí? Epidemiol Mikrobiol Imunol. 2015;64(3):130-8.
    11. Mosiej E, Augustynowicz E, Zawadka M, Dabrowski W, Lutyńska A. Strain Variation among Bordetella pertussis Isolates Circulating in Poland after 50 Years of Whole-Cell Pertussis Vaccine Use. J Clin Microbiol. 2011;49(4):1452-7. Go to original source... Go to PubMed...
    12. Locht C. Bordetella: Molecular mikrobiology. Wyomondham, Norfolk: Horizon Bioscience, 2007. p. 289. ISBN 978-1-904933-31-1.
    13. Raška K. Epidemiologie. 2. vyd. Praha: Státní zdravotnické nakladatelství, 1954. 611 s.
    14. Vysoká-Buriánová B. Epidemiologie. 1. vyd. Praha: Avicenum, 1981. 298 s.
    15. WHO. Immunization coverage. Fact sheet. Reviewed March 2016. [online]. [cit. 2016-04-02] Dostupný na www: http://www.who.int/mediacentre/factsheets/fs378/en/.
    16. WHO. Pertussis vaccines. WHO position paper. Wkly Epidemiol Rec. 2015;90(35):433-60. Go to PubMed...
    17. WHO. Pertussis vaccines. WHO pozition paper. Wkly Epidemiol Rec. 2005;80(4):31-9. Go to PubMed...
    18. Cherry JD. The 112-Year Odyssey of Pertussis and Pertussis Vaccines-Mistakes Made and Implications for the Future. J Pediatric Infect Dis Soc. 2019 Sep 25;8(4):334-341. Go to original source... Go to PubMed...
    19. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012;367(11):1012-9. Go to original source... Go to PubMed...
    20. Misegades LK, Winter K, Harriman K, Talarico J, Messonnier NE, Clark TA, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA. 2012;308(20):2126-32. Go to original source... Go to PubMed...
    21. Guiso N. Bordetella pertussis: why is it still circulating? J Infect. 2014;68(Suppl 1):S119-24. Go to original source... Go to PubMed...
    22. Glanz JM, McClure DL, Magid DJ, Daley MF, France EK, Salmon DA, et al. Parental refusal of pertussis vaccination is associated with an increased risk of pertussis infection in children. Pediatrics. 2009;123(6):1446-51. Go to original source... Go to PubMed...
    23. Cherry JD, Paddock CD. Pathogenesis and histopathology of pertussis: implications for immunization. Expert Rev Vaccines. 2014;13(9):1115-23. Go to original source... Go to PubMed...
    24. Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012; 367:1012-19. Go to original source... Go to PubMed...
    25. Liko J, Robison SG, Cieslak PR. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med 2013;3368: 581-2. Go to original source... Go to PubMed...
    26. Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012; 308:454-6. Go to original source... Go to PubMed...
    27. Smits K, Pottier G, Smet J, Dirix V, Vermeulen F, De Schutter I, et al. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination. Vaccine. 2013;32(1):111-8. Go to original source... Go to PubMed...
    28. Mills KH, Ross PJ, Allen AC, Wilk MM. Do we need a new vaccine to control the re-emergence of pertussis? Trends Microbiol. 2014;22(2):49-52. Go to original source... Go to PubMed...
    29. Higgs R, Higgins SC, Ross PJ, Mills KH. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol. 2012;5(5):485-500. Go to original source... Go to PubMed...
    30. Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Misiak A, et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog. 2013;9(4):e1003264. Go to original source... Go to PubMed...
    31. Warfel JM, Merkel TJ. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol. 2013;6(4):787-96. Go to original source... Go to PubMed...
    32. WHO Immunological Basis for Immunizations Series. Module 4: Pertussis. Update 2017
    33. Cherry JD. The 112-Year Odyssey of Pertussis and Pertussis Vaccines-Mistakes Made and Implications for the Future. J Pediatric Infect Dis Soc. 2019 Sep 25;8(4):334-341. Go to original source... Go to PubMed...
    34. Warfel JM, Merkel TJ. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol. 2013;6(4):787-96. Go to original source... Go to PubMed...
    35. Holubová J, Staněk O, Brázdilová L, Mašín J, Bumba L. Gorringe AR, et al. Acellular Pertussis Vaccine Inhibits Bordetella pertussis Clearance from the Nasal Mucosa of Mice. Vaccines (Basel). 2020; 8(4):695. Go to original source... Go to PubMed...
    36. Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol. 2001;39(12):4396-403. Go to original source... Go to PubMed...
    37. Elomaa A, Advani A, Donnelly D, Antila M, Mertsola J, Hallander H, He Q. Strain variation among Bordetella pertussis isolates in Finland, where the whole-cell pertussis vaccine has been used for 50 years. J Clin Microbiol. 2005;43(8):3681-7. Go to original source... Go to PubMed...
    38. Kallonen T, He Q. Bordetella pertussis strain variation and evolution postvaccination. Epert Rev Vaccines. 2009;8(7):863-75. Go to original source... Go to PubMed...
    39. Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ, de Greeff SC, Diavatopoulos D, Teunis P, Nagelkerke N, Mertsola J. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis. 2009;15(8):1206-13. Go to original source... Go to PubMed...
    40. Mooi FR, van Loo IH, King AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg Infect Dis. 2001;7(3 Suppl): 526-8. Go to original source... Go to PubMed...
    41. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun. 1998;66(2):670-5. Go to original source... Go to PubMed...
    42. Zavadilová J, Lžičařová D, Musílek M, Křížová P, Fabiánová K. Antigenní variabilita kmenů Bordetella pertussis izolovaných v letech 1967-2010 v České republice--možné vysvětlení vzestupu ne
    43. mocnosti pertusí? Epidemiol Mikrobiol Imunol. 2015;64(3):130-8. Go to original source...
    44. Barkoff AM, Mertsola J, Guillot S, Guiso N, Berbers G, He Q. Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland. Clin Vaccine Immunol. 2012;19(10): 1703-4. Go to original source... Go to PubMed...
    45. Hegerle N, Paris AS, Brun D, Dore G, Njamkepo E, Guillot S, et al. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin. Clin Microbiol Infect. 2012;18(9):E340-6. Go to original source... Go to PubMed...
    46. Safarchi A, Octavia S, Wu SZ, Kaur S, Sintchenko V, Gilbert GL, et al. Genomic dissection of Australian Bordetella pertussis isolates from the 2008-2012 epidemic. J Infect. 2016;72(4):468-77. Go to original source... Go to PubMed...
    47. Lam C, Octavia S, Ricafort L, Sintchenko V, Gilbert GL, Wood N, et al. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg Infect Dis. 2014;20(4):626-33. Go to original source... Go to PubMed...
    48. Queenan AM, Cassiday PK, Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med. 2013;368(6):583-4. Go to original source... Go to PubMed...
    49. Pawloski LC, Queenan AM, Cassiday PK, Lynch AS, Harrison MJ, Shang W, et al. Prevalence and Molecular Characterization of Pertactin-Deficient Bordetella pertussis in the United States. Clin Vaccine Immunol. 2014;21(2):119-25. Go to original source... Go to PubMed...
    50. Martin SW, Pawloski L, Williams M, Weening K, DeBolt C, Qin X, et al. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage. Clin Infect Dis. 2015;60(2):223-7. Go to original source... Go to PubMed...
    51. Barkoff AM, Mertsola J, Pierard D, Dalby T, Hoegh SV, Guillot S, et al. Pertactin-deficient Bordetella pertussis isolates: evidence of increased circulation in Europe, 1998 to 2015. Euro Surveill. 2019;24(7):1700832. Go to original source... Go to PubMed...
    52. Clarke M, McIntyre PB, Blyth CC, Wood N, Octavia S, Sintchenko V, et al. The relationship between Bordetella pertussis genotype and clinical severity in Australian children with pertussis. J Infect. 2016;72(2):171-8. Go to original source... Go to PubMed...
    53. Ma L, Caulfield A, Dewan KK, Harvill ET. Pertactin-Deficient Bordetella pertussis, Vaccine-Driven Evolution, and Reemergence of Pertussis. Emerg Infect Dis. 2021;27(6):1561-1566. Go to original source... Go to PubMed...
    54. Fabiánová K., Zavadilová J., Lenz P., Šebestová H., Kynčl J. Surveillance pertuse a parapertuse v České republice v pandemickém roce 2020. Zprávy CEM (SZÚ, Praha) 2021; 30(9): 276-285.
    55. Fabiánová K. Polymorfismus Bordetella pertussis a vývoj nových očkovacích látek proti pertusi. Vakcinologie. 2016,10(4)150-154.

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content